IL273125A - Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them - Google Patents
Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking themInfo
- Publication number
- IL273125A IL273125A IL273125A IL27312520A IL273125A IL 273125 A IL273125 A IL 273125A IL 273125 A IL273125 A IL 273125A IL 27312520 A IL27312520 A IL 27312520A IL 273125 A IL273125 A IL 273125A
- Authority
- IL
- Israel
- Prior art keywords
- abiraterone
- administration
- formation
- methods
- pharmaceutical formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562081P | 2017-09-22 | 2017-09-22 | |
| PCT/US2018/051914 WO2019060525A1 (en) | 2017-09-22 | 2018-09-20 | PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL273125A true IL273125A (en) | 2020-04-30 |
Family
ID=65808544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273125A IL273125A (en) | 2017-09-22 | 2020-03-08 | Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190091339A1 (https=) |
| EP (1) | EP3684371A4 (https=) |
| JP (2) | JP2020534320A (https=) |
| KR (1) | KR20200064993A (https=) |
| CN (1) | CN111107852A (https=) |
| AU (1) | AU2018335391A1 (https=) |
| CA (1) | CA3075095A1 (https=) |
| IL (1) | IL273125A (https=) |
| MA (1) | MA50189A (https=) |
| WO (1) | WO2019060525A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020240017A1 (en) * | 2019-03-18 | 2021-11-04 | AustinPx, LLC | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof |
| CN110141556B (zh) * | 2019-06-24 | 2021-07-13 | 李建恒 | 一种阿比特龙包合物片剂及其制备方法 |
| WO2021086565A1 (en) * | 2019-11-01 | 2021-05-06 | Dispersol Technologies, Llc | Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof |
| CA3160834C (en) * | 2019-11-14 | 2024-06-11 | Suven Life Sciences Limited | Amorphous pharmaceutical compositions of abiraterone acetate |
| US20220401579A1 (en) * | 2019-11-30 | 2022-12-22 | Dispersol Technologies, Llc | Inclusion complexes of pharmaceuticals and cyclic oligomers |
| KR102363026B1 (ko) * | 2019-12-26 | 2022-02-16 | 보령제약 주식회사 | 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 전립선암 예방 또는 치료용 약학적 조성물 |
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6073043B2 (ja) * | 2007-08-21 | 2017-02-01 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 医薬品適用のための熱−動力学的混合 |
| US9040080B2 (en) * | 2008-10-21 | 2015-05-26 | Southwest Research Institute | Processing of heat-sensitive active agents |
| CN103813794A (zh) * | 2011-07-18 | 2014-05-21 | 拓凯制药公司 | 用于治疗前列腺癌的新型组合物及方法 |
| HRP20191982T4 (hr) * | 2011-11-30 | 2023-01-06 | Astrazeneca Ab | Kombinacijsko liječenje raka |
| GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014009437A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
| US20140287039A1 (en) * | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| WO2015032873A1 (en) * | 2013-09-06 | 2015-03-12 | Synthon B.V. | High-load pharmaceutical compositions comprising abiraterone acetate |
| WO2016051368A1 (en) * | 2014-10-01 | 2016-04-07 | Mylan Laboratories Ltd | Complex of amorphous empagliflozin and a cyclodextrin |
| WO2017037647A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical compositions of abiraterone |
-
2018
- 2018-09-20 WO PCT/US2018/051914 patent/WO2019060525A1/en not_active Ceased
- 2018-09-20 CN CN201880061714.XA patent/CN111107852A/zh active Pending
- 2018-09-20 US US16/136,413 patent/US20190091339A1/en not_active Abandoned
- 2018-09-20 KR KR1020207008684A patent/KR20200064993A/ko not_active Ceased
- 2018-09-20 AU AU2018335391A patent/AU2018335391A1/en not_active Abandoned
- 2018-09-20 JP JP2020516620A patent/JP2020534320A/ja active Pending
- 2018-09-20 MA MA050189A patent/MA50189A/fr unknown
- 2018-09-20 CA CA3075095A patent/CA3075095A1/en active Pending
- 2018-09-20 EP EP18858759.6A patent/EP3684371A4/en not_active Withdrawn
-
2020
- 2020-03-08 IL IL273125A patent/IL273125A/en unknown
-
2023
- 2023-09-28 JP JP2023167274A patent/JP2023182674A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023182674A (ja) | 2023-12-26 |
| JP2020534320A (ja) | 2020-11-26 |
| WO2019060525A1 (en) | 2019-03-28 |
| US20190091339A1 (en) | 2019-03-28 |
| EP3684371A4 (en) | 2021-05-19 |
| CN111107852A (zh) | 2020-05-05 |
| MA50189A (fr) | 2021-05-19 |
| CA3075095A1 (en) | 2019-03-28 |
| AU2018335391A1 (en) | 2020-03-26 |
| KR20200064993A (ko) | 2020-06-08 |
| EP3684371A1 (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273125A (en) | Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them | |
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| IL287749A (en) | Compositions for administering implantable drugs and methods of their use | |
| EP4335517B8 (en) | Administration and dosage of diaminophenothiazines | |
| GB201817116D0 (en) | Pharmaceutical preparation of palbociclic and preparation method thereof | |
| IL256364A (en) | Pharmaceutical formulations containing tenofovir and emtricitabine | |
| GB201620066D0 (en) | Solid Pharmaceutical dosage formulations and processes | |
| EP3209681A4 (en) | Pharmaceutical compositions comprising peptide variants and methods of use thereof | |
| PT3380525T (pt) | Formulações farmacêuticas e métodos que as utilizam | |
| IL266132A (en) | Pharmacological formulations and methods for their preparation | |
| IL271596A (en) | Preparations for administering drugs and methods of using them | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| IL274893A (en) | Pharmaceutical formulation of 3 alpha-ethenyl-3 beta-hydroxyandrostan-17-one oxime | |
| EP3532052A4 (en) | DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS | |
| IL286416A (en) | Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| EP3506947A4 (en) | PHARMACEUTICAL FORMULATIONS OF REGADENOSONE | |
| EP3497080A4 (en) | PHARMACEUTICAL FORMULATIONS AND THEIR USE | |
| IL252080B (en) | Oral administration of drugs that are unstable or poorly absorbed | |
| EP3612185A4 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING POH DERIVATIVES AND METHODS OF USE | |
| ZA201705329B (en) | Pharmaceutical formulations of racecadotril | |
| GB201710382D0 (en) | Administration and dosage of Diaminophenothiazines | |
| HK40031500A (en) | Extended release pharmaceutical formulation and methods of treatment | |
| GB201612863D0 (en) | Administration and dosage of diaminophenothiazines | |
| AU2016903741A0 (en) | Vaccine comprising drug and parasite administration |